Table 2
Treatments Received by Study Patients (n=1037)

<table>
<thead>
<tr>
<th>Pharamaceutical treatment</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics</td>
<td>925 (89.2)</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>583 (56.2)</td>
</tr>
<tr>
<td>ARB</td>
<td>374 (36.1)</td>
</tr>
<tr>
<td>ACE inhibitors and/or ARB</td>
<td>957 (92.3)</td>
</tr>
<tr>
<td>MRA</td>
<td>688 (66.4)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>794 (76.6)</td>
</tr>
<tr>
<td>Ivalbradine</td>
<td>74 (7.2)</td>
</tr>
<tr>
<td>Statins</td>
<td>786 (75.8)</td>
</tr>
<tr>
<td>Antiplatelet agents</td>
<td>622 (60.2)</td>
</tr>
<tr>
<td>Oral anticoagulants</td>
<td>414 (39.9)</td>
</tr>
</tbody>
</table>

Nonpharmaceutical treatment

Ventricular resynchronization: 65 (6.3)
Implantable cardioverter-defibrillator: 96 (9.1)
Follow-up in HF unit: 208 (21.0)

ACE, angiotensin convertor enzyme; ARB, angiotensin receptor blockers; HF, heart failure; MRA, mineralocorticoid receptor antagonist.

(43%) than in the VIDA-IC study. In the most recent long-term study, the rate of use of these 3 therapeutic classes was 92%, 92%, and 67%, respectively. We can conclude that, despite advances in recent years in the treatment of systolic HF, there is still plenty of room for improvement in our patients, particularly in terms of use of beta-blockers, MRA, and ivabradine.

CONFLICTS OF INTEREST

Pfizer S.L.U. is the sponsor of the VIDA-IC study and provided funding. The authors have received honoraria from Pfizer S.L.U. for the design of the study and the drafting and review of this article.

Manuel Anguita, Josep Comin-Coletr, Francesc Formiga, Luis Almenar, Marisa Crespo-Leiro, and Luis Manzano, on behalf of the investigators of the VIDA-IC Study

*Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
*Servicio de Cardiología, Hospital del Mar, Barcelona, Spain
*Servicio de Medicina Interna, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
*Servicio de Cardiología, Hospital Universitario La Fe, Valencia, Spain
*Servicio de Cardiología, Hospital Universitario A Coruña, A Coruña, Spain
*Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, Spain

*Corresponding author:
E-mail address: manuelp.anguita.sspa@juntadeandalucia.es
(M. Anguita).

Available online 27 June 2014

REFERENCES


Direct Percutaneous Implantation of an Edwards-SAPIEN Valve in Tricuspid Position in a Degenerated Bioprosthesis in a Patient With Ebstein Anomaly

Implante directo de válvula percutánea Edwards-SAPIEN en posición tricuspidae sobre bioprótesis degenerada en paciente con enfermedad de Ebstein

To the Editor,

The percutaneous implantation of prosthetic heart valves in degenerated bioprostheses in different positions has provided an alternative to surgery in patients with congenital or acquired heart disease who are at high surgical risk. There is little experience with percutaneous implantation of prostheses in tricuspid position. We report the case of a patient with a stenotic tricuspid bioprosthesis who was treated with a percutaneously implanted prosthesis. To our knowledge, this was the first time this intervention was performed in Spain.

The patient was a 38-year-old man, diagnosed as having Ebstein anomaly with an atrial septal defect, who had undergone tricuspid valve replacement by a 31-mm Biocor bioprosthesis and atrial septal defect closure at the age of 23 years. During the postoperative period, he developed acute thrombosis that was resolved with fibrinolysis and had another episode 6 months later coinciding with the discontinuation of antiocoagulation therapy. He was found to have advanced ativoventricular block and underwent implantation of a DDD pacemaker with an intracavitary atrial lead and an epicardial ventricular lead. Over the preceding 3 years, he had shown classic signs of right heart failure that required diuretic therapy. An echocardiogram revealed degenerative changes in the bioprosthesis that were causing marked stenosis (peak gradient, 13 mmHg; mean gradient, 9 mmHg) with mild regurgitation, in addition to severe right ventricular dysfunction. The patient underwent catheterization, which revealed a tricuspid diastolic pressure gradient of 10 mmHg, with a mean right atrial pressure of 14 mmHg and a cardiac index of 1.9 L/min/m². Given the high risk, both valve replacement and surgery to perform the Glenn procedure were ruled out, and he was scheduled for percutaneous prosthesis implantation.

The procedure was carried out with general anesthesia. A right jugular vein approach was employed to implant a temporary pacemaker at the level of the coronary sinus for rapid pacing during
the valve implantation. Using a left femoral venous approach because the right femoral vein was occluded, the tricuspid bioprosthesis was crossed with a balloon catheter, and a high-support guide wire was introduced at the level of the right ventricle. Once the vein had been prepared with several 12-Fr to 20-Fr dilators, a 20-Fr introducer was placed. Subsequently, with no predilation, we implanted a 29-mm Edwards-SAPIEN XT prosthesis (Edwards Lifesciences; Irvine, California, United States), mounted in the direction contrary to the usual manner (implantation in aortic position via femoral access), over the NovaFlex+ release system (Edwards Lifesciences) and within the degenerated bioprosthesis. There were no technical difficulties either along the delivery route or at the point where the prosthesis crossed over the bioprosthesis. As a reference for the implantation, we used the radiopaque annulus of the bioprosthesis in right anterior oblique projection, where it remained perpendicular. The balloon was slowly inflated with rapid pacing, and nearly the entire percutaneously implanted prosthesis was placed in the ventricular part of the annulus of the bioprosthesis to ensure that this new prosthesis covered the degenerated leaflets of the first device (Figure 1). There was an immediate deterioration in right ventricular function, probably related to the rapid pacing and lengthy procedure employed for prosthesis implantation. An echocardiogram performed 24 hours later showed recovery of right ventricular function and normal function of the prosthesis (peak gradient, 6 mmHg; mean gradient, 3.5 mmHg) (Figure 2). One month later, the patient showed no signs of right heart failure and was being treated indefinitely with acenocoumarol (which he previously had been taking) and acetylsalicylic acid, in addition to a 3-month regimen of clopidogrel.

The choice of the 29-mm Edwards-SAPIEN model was based on the size of the degenerated bioprosthesis, which measured 31 mm and had an internal diameter of 29 mm. The alternative prosthetic valve for percutaneous implantation in tricuspid position is the Melody (Medtronic Inc., Minneapolis, United States), but it was inappropriate because the maximum available diameter is 22 mm, which would have been too small for the case we report here. There is little experience with the percutaneous implantation of an Edwards-SAPIEN prosthesis over a bioprosthesis in tricuspid position, there being around 20 published cases. In most of them, placement was achieved using a direct transatrial or a transjugular approach, whereas there have only been 6 cases involving femoral access. The transatrial and transjugular approaches enable direct access to the tricuspid valve, making the procedure simpler to perform. However, the inconvenience of the transatrial approach is that it requires thoracotomy, and the drawback to the transjugular approach is the need for introducers of a larger gauge, as this technique requires a transapical delivery system, which, for a 29-mm prosthesis, would involve a 26-Fr sheath. This, in turn, would necessitate surgical closure of the jugular vein. In the 6 reported cases of femoral access, the bioprosthesis was previously dilated. This is the first report of a case of direct implantation with no predilation, via femoral access. The risk of prosthesis migration during implantation is probably lower when predilation is not performed, and the material within the degenerated bioprosthesis is usually friable, and thus is usually easy to cross through. Moreover, embolization of this material is reduced with direct implantation.1

This case demonstrates the feasibility of implanting an Edwards-SAPIEN prosthesis at the level of a degenerated tricuspid bioprosthesis using the femoral approach and without predilation. A larger number of cases and follow-up over several years will be necessary to confirm the utility of this new strategy for valve therapy.
A Recessive Inheritance Pattern Contributes to Arrhythmogenic Biventricular Cardiomyopathy

Hericia autosómica recesiva como causa de miocardiopatía arritmogénica biventricular

To the Editor,

Arrhythmogenic right ventricular dysplasia (ARVD) is a genetic disease with a mutation rate of 50% to 60% in desmosomal genes. The disease is usually inherited in an autosomal dominant pattern, except for Naxos disease and Carvajal syndrome, which have specific phenotypic characteristics (palmoplantar keratoderma, wooly hair, etc) and are inherited in an autosomal recessive pattern. Since the first report of an association between the desmoglein-2 gene (DSG2) and the development of ARVD in 2006,1 numerous mutations have been described, almost all of which are heterozygous with autosomal dominant behavior. This gene can be inherited as compound or digenic heterozygosity.2 It has recently been shown that mutations in this gene can exhibit an autosomal recessive pattern in the absence of cardiocutaneous syndrome, although the available data on this issue are very scarce.3,4 We describe the clinical spectrum and autosomal recessive mode of transmission.

REFERENCE

http://dx.doi.org/10.1016/j.rec.2014.03.013